Precigen announces further advancement of ultracar-t® platform with first patient dosed in phase 1/1b dose escalation/dose expansion study of prgn-3007 in advanced ror1+ hematological and solid tumors

– milestone represents the first patient dosed with the next generation ultracar-t, incorporating pd-1 checkpoint inhibition in addition to three effector genes – – proprietary technology for checkpoint blockade intrinsic to ultracar-t cells avoids the need for combination with a systemic checkpoint inhibitor, potentially limiting cost and systemic toxicity – germantown, md. , march 29, 2023 /prnewswire/ -- precigen, inc. (nasdaq: pgen), a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives of patients, today announced that the first patient has been dosed in the phase 1/1b dose escalation/dose expansion study (clinical trial identifier: nct05694364) of prgn-3007 in advanced ror1-positive (ror1+) hematological and solid tumors.
PGEN Ratings Summary
PGEN Quant Ranking